Diasol sold unapproved citric acid hemodialysis disinfectants and had quality system violations, FDA says.
What happened
FDA inspected Diasol’s Phoenix, AZ facility from July 21 to August 19, 2025. FDA found the firm’s 20% and 50% citric acid solutions for cleaning, decalcifying, and heat-disinfecting hemodialysis machines lacked required premarket approval or IDE and were not 510(k)-notified. The inspection also found Quality System violations, including acceptance limits outside the chosen standard, missing dextrose results before release, and inadequate validation of drum cleaning, mixing, water systems, and microbial testing.
What FDA found
The 20% and 50% citric acid solutions for cleaning, decalcifying, and heat-disinfecting hemodialysis machines were adulterated and misbranded because they lacked premarket approval or an IDE and were not 510(k)-notified.
21 U.S.C. § 351(f)(1)(B); 21 U.S.C. § 352(o); 21 U.S.C. § 360(k)Final acceptance procedures did not ensure electrolyte levels met the selected standard, and some batches were released without required dextrose test results.
21 CFR § 820.80(d)Cleaning of reusable drums and mixing and water-system processes were not adequately validated, including missing raw data, unresolved failed tests, and an unvalidated mixing setup.
21 CFR § 820.75(a)Microbiological testing and water-system monitoring were not properly implemented or controlled, including non-sterile sampling, expired syringes, out-of-range incubator temperatures, and unmonitored water parameters.
21 CFR § 820.70(a)Warehouse temperature and humidity were not adequately monitored or controlled for finished products and raw materials requiring dry or cool storage.
21 CFR § 820.70(a)
What FDA wants
FDA tells Diasol to correct the unapproved-device status and Quality System violations, including updating DMRs and acceptance limits, stopping use of noncompliant electrolyte ranges, and providing evidence of the planned corrections and validations. No response deadline is stated in the provided letter text.
Who should pay attention
- dialysis clinics and providers
- companies buying or distributing Diasol products
- quality teams at dialysis solution and device manufacturers
This is a summary. Read the original letter on fda.gov.